SNDX Syndax Pharmaceuticals, Inc.

9.83
0  -4%
Previous Close 10.26
Open 10.31
Price To book 2.22
Market Cap 179.34M
Shares 18,244,000
Volume 174,747
Short Ratio 2.80
Av. Daily Volume 91,592

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 part of Phase 1b/2 trial recently initiated - as noted March 2, 2017.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 enrolling as of November 2016. Poster presentation at ASCO June 3, 2017. Abstract 9529.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 3 PFS data due by the end of 2017.
E2112
HR+, HER2- breast cancer

Latest News

  1. Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
  2. Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
  3. Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
  4. Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  5. Edited Transcript of SNDX earnings conference call or presentation 2-Mar-17 9:30pm GMT
  6. Syndax reports 4Q loss
  7. Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update
  8. Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
  9. Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
  10. Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017
  11. Syndax Appoints Richard P. Shea as Chief Financial Officer
  12. Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board
  13. Syndax Pharmaceuticals (SNDX) Looks Good: Stock Up 14.3%
  14. Syndax Pharma Inks Key Agreement With National Cancer Institute
  15. Why Syndax Pharmaceuticals (SNDX) Could Be Positioned for a Slump
  16. Edited Transcript of SNDX earnings conference call or presentation 10-Nov-16 9:30pm GMT